gelscom

What gelscom does

Gelscom SAS is a privately-held French medical device company founded in July 2005 and headquartered in Hérouville-Saint-Clair, Normandy. The company operates two business lines: industrial development, production, and comarketing of its own injectable gel-based Class III medical devices, and consulting services for pharmaceutical laboratories and biotechnology companies focused on business development strategy and market entry. Its core technology centers on proprietary injectable gel formulations developed from French academic research patents originating at INRA, INSERM, CERMAV, ESPCI, and university hospitals, with intellectual property held by partner GELNESIS and exclusive exploitation rights licensed to Gelscom. The percutaneous, minimally invasive administration technique enables procedures to be performed in a half-day hospital setting without general anesthesia.

Gelscom markets three products built on this technology platform. DiscoGel is a Class III medical device for treating herniated discs at lumbar and lumbo-sacral levels of the spine; it received its CE mark in October 2007 and achieved EU MDR 2017/745 certification in January 2023. ScleroGel kit is a Class III device for treating rare/orphan genetic diseases affecting low blood flow vessels, CE marked in January 2012. KYSTOGEL is a third device under investigation for resorbing bone cysts and facilitating bone reconstruction, with its trademark filed.

The company generates revenue through hardware sales of its medical devices via exclusive worldwide distributor partnerships segmented by therapeutic specialty — DiscoGel through spine/vertebral distributors and ScleroGel through vascular disease specialists — plus professional services consulting revenue. Gelscom is ISO 13485 certified (most recently ISO 13485:2016 in January 2016), registered as a manufacturer with the French National Agency for Medicines and Health Products Safety (ANSM, identifier FR-MF-000000163), and operates its own R&D laboratory equipped with a clean room. The company is majority-owned by its three founders — Michaël Le Bail (President), J. David Grausz (Business Development and IP Director), and Philippe Clousier (CFO) — and has not raised external venture or private equity capital.

Name

gelscom

Legal name

Gelscom SAS

Website

https://gelscom.com

Company type

Private

Founded year

2005

Operating status

Operating

Short description

Gelscom SAS is a privately-held French medical device company that develops and commercializes Class III injectable gel products, including DiscoGel for herniated discs and ScleroGel for rare vascular diseases, sold worldwide through exclusive distributor partnerships, and provides business development consulting to pharmaceutical and biotech firms.

Ownership category

akta.pro rank

Product category

Class III Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL)

Keywords

• Injectable gel medical devices
• Minimally invasive percutaneous procedures
• Class III medical devices
• Herniated disc treatment
• Pharma biotech consulting

Headquarters

HQ city

Hérouville-saint-clair

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

1. Industrial Development and Production of Own Products: Development, production, and comarketing of proprietary injectable pharmaceutical medical devices including DiscoGel and ScleroGel kit. Products are Class III medical devices distributed worldwide through exclusive distributors.
2. Consulting Services: Assisting pharmaceutical laboratories and biotech companies to improve their business development strategy to ensure more rapid market entry with better products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Gelscom develops, manufactures, and comarkets proprietary injectable gel-based Class III medical devices used in minimally invasive percutaneous procedures for hospitals. Its main products are DiscoGel (treatment of herniated discs at lumbar and lumbo-sacral levels) and ScleroGel kit (treatment of rare genetic diseases affecting low blood flow vessels). The company also provides consulting services to pharmaceutical laboratories and biotech companies to improve their business development strategy and accelerate market entry.

Product overview

Gelscom develops and commercializes injectable gel-based medical devices for minimally invasive percutaneous procedures. The company offers three main products: DiscoGel (for treating herniated discs), ScleroGel kit (for treating genetic diseases affecting blood vessels), and KYSTOGEL (under investigation for bone cyst treatment). All products are Class III medical devices designed for hospital use requiring fluoroscope-equipped operating blocks. Distribution is managed through exclusive worldwide distributors specializing in relevant medical specialties.

Differentiator

Problem solved

Functional benefit

Brands

• DiscoGel: Class III medical device for treating patients with herniated disc at lumbar and lumbo-sacral levels of the spine. Minimally invasive percutaneous procedure.
• ScleroGel kit
• KYSTOGEL
• GELNESIS

Products and services

• DiscoGel Class III injectable gel medical device for treating patients with herniated discs at lumbar and lumbo-sacral levels of the spine. The minimally invasive percutaneous procedure is typically performed as a half-day hospital procedure without general anesthesia. First CE marked in 2007 and subsequently certified under the EU MDR 2017/745 in January 2023. Marketed to interventional radiologists, neuroradiologists, and spine specialists through exclusive distributors worldwide.
• ScleroGel kit Class III medical device used to treat genetic diseases affecting low blood flow vessels (orphan/rare genetic disease). Marketed worldwide through exclusive distributors specializing in vascular disease.
• Pharmaceutical and Biotech Consulting Services Advisory services assisting pharmaceutical laboratories and biotech companies to improve their business development strategy in order to ensure more rapid market entry with better products.

Quantifiable outcome

• DiscoGel procedure performed in half-day hospital setting without general anesthesia
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered minor, core and major.

• PolePharmaminorOthers · 28 September 2005Competition organizer; Gelscom won innovation prize at ProcessPharma conference in Dreux on 28 September 2005.
• GELNESIScoreStrategic or Co-development PartnerGELNESIS collaborated with Gelscom on research and holds the patents and intellectual property for injectable gel technology. Products are developed through this partnership with Gelscom holding exclusive exploitation rights.
• INRA (Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement)majorStrategic or Co-development PartnerFrench national research institution collaborating with Gelscom for research and development of medical products.
• INSERM (Institut National de la Santé et de la Recherche Médicale)majorStrategic or Co-development PartnerFrench national medical research institute collaborating with Gelscom for R&D activities.
• CERMAV (Centre de Recherche sur les Macromolécules Végétales)majorStrategic or Co-development PartnerResearch center collaborating with Gelscom on macromolecule-based research for medical applications.
• University HospitalsmajorStrategic or Co-development PartnerAcademic hospital partners collaborating with Gelscom on clinical research and product development.
• ESPCI (École Supérieure de Physique et de Chimie Industrielles de Paris)minorStrategic or Co-development PartnerEngineering school partner for specialized research collaboration.
• Pharmacy UniversitiesminorStrategic or Co-development PartnerAcademic pharmacy school partners in research collaborations.
• Journal of Spinal Disorders & TechniquesminorOthersPeer-reviewed academic journal that published DiscoGel research in October 2007.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• AngioDynamics: US-listed medical device company selling sclerotherapy and vascular products (e.g. Sotradecol, Varithena via legacy BTG assets), directly comparable to ScleroGel as a Class III injectable for vascular specialists.
• joimax: German privately-held specialist in minimally invasive endoscopic spine surgery, directly comparable to DiscoGel as an alternative percutaneous/herniated disc treatment offered to similar specialist physicians.
• BTG International (Boston Scientific): Now part of Boston Scientific, BTG previously owned Varithena (polidocanol injectable foam) and other sclerotherapy assets — a direct commercial analogue to ScleroGel for vascular specialists.

Broad incumbents

• Integra LifeSciences: Diversified medical device company with neurosurgery, orthobiologics and regenerative-tissue products that overlap with Gelscom's percutaneous gel/regenerative platform and hospital specialty channel.
• Globus Medical: Spine-focused medical device company offering minimally invasive and percutaneous solutions for vertebral applications that compete for the same interventional radiology/neuroradiology budgets as DiscoGel.
• Hologic: Diversified women's-health and interventional device incumbent with hospital-channel presence and minimally invasive procedure franchises that share go-to-market dynamics with DiscoGel and ScleroGel.
• Medtronic: Global medical device leader with a large spine portfolio (Kyphon, bone cements, vertebroplasty) and a broad hospital distribution footprint comparable to DiscoGel's end-user environment.
• Stryker: Diversified orthopaedic and spine medical device incumbent with vertebral/percutaneous spine products; overlaps with DiscoGel in hospital interventional channels.

Emerging players

• Merz Aesthetics: Sells injectable sclerosing agents (e.g. Asclera) for vascular specialists, comparable to ScleroGel in the same outpatient vascular sclerotherapy channel.
• Elliquence: Specialist in percutaneous disc decompression (Disc-FX), targeting the same herniated-disc interventional segment as DiscoGel with a different energy-based modality.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about gelscom